{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"TESAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect or was medically significant. TEAEs were defined as AEs if one of the following conditions met: emerged after the time of first dose administration, having been absent prior to the first dose; re-emerged, having been present but stopped prior to the time of first dose administration; worsened in severity after the time of first dose administration relative to the pretreatment state, when the AE was continuous.","groups":[{"description":"Participants with ES received tazemetostat 1600 mg QD orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG000","title":"ES 1600 mg: Cohort 8"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included all participants in the ITT population who had at least 1 post-dose safety observation recorded.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 148 weeks","title":"Cohort 8: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}